Tumour re-differentiation effect of retinoic acid: A novel therapeutic approach for advanced thyroid cancer

Current Pharmaceutical Design

Volumn 11, Issue 19, 2005, Pages 2525-2531

  Coelho, Sabrina M ^a   Vaisman, Mário ^a   Carvalho, Denise P ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CELL NUCLEUS RECEPTOR; FLUORODEOXYGLUCOSE; IODINE; IODINE 131; ISOTRETINOIN; LIOTHYRONINE; RADIOACTIVE IODINE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; RETINOL DERIVATIVE; SODIUM IODIDE SYMPORTER; THYROTROPIN; THYROXINE; THYROXINE DEIODINASE;

ADVANCED CANCER; APOPTOSIS; BLOOD TOXICITY; CANCER HORMONE THERAPY; CARCINOMA CELL; CELL PROLIFERATION; CELL TYPE; CLINICAL STUDY; COUGHING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; FOLLOW UP; HAIR LOSS; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; LIVER DYSFUNCTION; METASTASIS; MITOSIS; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; THYROID CANCER; THYROID CARCINOMA; THYROID FUNCTION; THYROID SURGERY; TUMOR CELL LINE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; TECHNOLOGY, PHARMACEUTICAL; THYROID NEOPLASMS; TRETINOIN;

EID: 21044449463     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367490     Document Type: Review

References (72)

1. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002; 9: 227-47.
2. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
3. Goretzki PE, Simon D, Frilling A, Witte J, Reiners G, Grussen M, et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 1994; 80: 1131-34.
4. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16: 34-41.
5. Marcus M, Coulton AM. Fat-soluble vitamins A, K, E. In: Hadman JG, Limbird LE, Gilman AG, Eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. Mc Graw Hill 2000; 1773-92.
6. Castaigne S, Chomienne C, Daniel MT, Ballermi P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukaemia. I. Clinical results. Blood 1990; 76: 1704-9.
7. Lippman SM, Meyskens FL. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Int Med 1987; 107: 499-501.
8. Saade M, Debahy NE, Houjeily S. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: a case report. J Chemother 1999; 11: 313-7.
9. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000; 85: 2889-96.
10. Schmutzler C, Winzer R, Maissner-Weigl J, Köhrle J. Retinoic acid incerases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of function symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997; 240: 832-8.
11. Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994; 79: 791-8.
12. Schmutzler C, Brtko J, Bienert K, Köhrle J. Effects of retinoids and role of retinoic receptor in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 1996; 104 (suppl 4): 16-9.
13. Van Herle AJ, Agatep ML, Padua DN, totanes TL, Canlapan DV, Van Herle HML, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990; 71: 755-63.
14. Simon D, Köhrle J, Schmutzler C, Mainz K Reiners C, Röher HD. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996; 104 (suppl 4): 13-5.
15. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22: 569-574.
16. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39: 1903-6.
17. Schmutzler C, Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000; 10: 393-405.
18. Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med 2002; 29: 775-82.
19. Grüning T, Tiepolts C, Zöphel K, Bradow J, Kropp J, Franke W-G. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003; 148: 395-402.
20. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004; 27: 334-9.
21. - - symporter mRNAs in dog thyroid. Mol Cell Endocrinol 1997; 131:195-203.
22. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroid tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland and gastric mucosa. J Clin Endocrinol Metab 1998; 83:1746-51.
23. Carrasco N. Iodide transport in the thyroid gland. Biochem Biophys Acta 1993; 1154:65-82.
24. Golstein P, Abramow M, Dumont JE, Beauwens R. The iodide channel of the thyroid: a plasma membrane vesicle study. Am J Physiol 1992; 263: C590-7.
25. Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P. Functional characterisation of pendrin in a polarised cell system. Evidence for pendrin-mediated apical iodide efflux. J Biol Chem 2004; 279: 13004-10.
26. Lacroix L, Pourcher T, Magnon C, Bellon N, Talbot M, Intaraphairot T, et al. Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters. J Clin Endocrinol Metab 2004; 89: 1423-8.
27. Dai G, Levy O, Carrasco N. Cloning and characterisation of the iodide transporter. Nature 1996; 379: 458-60.
28. Smanik PA, Liu Q, Furminger TL, Ryu k-Y, Xing S. Mazaferri FL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun, 1996; 226:339-45.
29. Riedel C, Levy O, Carrasco, N. Post-transcriptional regulation of the sodium/iodide symporter (NIS) by thyrotropin. J Biol Chem 2001; 276:21458-63.
30. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM. Induction of follicule formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 2000; 167:125-35.
31. Kawaguchi A, Ikeda M, Endo T, Kogai T, Miyazaki A, Onaya T. Transforming growth factor-β1 suppresses thyrotropin-induced Na/I symporter messenger RNA and protein levels in FRTL-5 rat thyroid cells. Thyroid 1997; 7: 789-94.
32. Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999; 9: 821-30.
33. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-28.
34. Ryu KY, Tong Q, Jhiang SM. Promoter characterisation of the human Na+/I- symporter. J Clin Endocrinol Metab 1998; 83: 3247-51.
35. Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organisation, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997; 138, 3555-8.
36. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumours. J Clin Endocrinol Metab 1998; 83:2493-6.
37. Lazar V, Bidart JM, Caliou B, Mahe C, Lacroix L, Filetti S, et al. Expression of Na/I symporter gene in human thyroid tumours: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999; 84:3228-34.
38. Ringel MD, Anderson J, Souza SL, Burch HB, Tambascia M, Shriver CD, et al. Expresion of sodium iodide symporter and thyroglobulin genes reduced in papillary thyroid cancer. Mod Pathol 2001; 14:289-96.
39. Satio T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998; 101: 1296-300.
40. - symporter (NIS) in a larger sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001; 86: 2697-700.
41. Tonacchera M, Viacava P, Agretti P, de Marco G, Perri A, di Cosmo C, et al. Benign nonfunctioning thyroid adenornas are characterised by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. J Clin Endocrinol Metab 2002; 87: 352-7.
42. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjuvant to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab 1976; 42:105-11.
43. Koong S-S, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, et al. Lithium as a potential adjuvant to 1311 therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912-6.
44. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 3430-5
45. - -symporter gene methylation status. J Clin Endocrinol Metab 1999; 84: 2449-57.
46. Eigelberger MS, Wong MG, Duh QY, Clark OH. Pherylacetate enhances the antiproliferative effect retinoic acid in follicular thyroid cancer. Surgery 2001; 130:931-5.
47. Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In: The retinoids: Biology, chemistry and Medicine. 2nd edition. Sporn MB, Roberts AB, Goodman DS, eds. Raven Press, New York, 1994; 573-95.
48. Giguère V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 1994; 15: 61-79.
49. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukaemia. Trends Genet 1999; 15: 179-84.
50. Khuri FR, Lotan R, Kemp BL, et al. Retinoic acid receptors-β as a prognostic indicator in stage I non-small cell lung cancer. J Clin Oncol 2000; 18: 2798-804.
51. Bradender J, Danenberger KD, Metzger R, et al. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 2002; 8: 438-43.
52. Xu X-C, Wong WYL, Goldberg L, Baer SC, Wolf JE, Ramsdell WM, et al. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res 2001; 61:4306-10.
53. Marshall GM, Cheung B, Stacey KP, Camacho ML, Simpson AM, Kwane E, et al. Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. Oncogene 1995; 11: 485-91.
54. Rochaix P, Monteil-Onteniente S, Rochette-Egly C, Caratero C, Voigt JJ, Jozan S. Reduced expression of retinoic acid receptor beta protein (RARβ) in human papillary thyroid carcinoma: immunohistochemical and Western blot study. Histopathology 1998; 33: 337-41
55. Schmutzler C, Brtko J, Jakobs TC, Meissner-Weigl J, Simon D, Goretzki PE, et al. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998; 76:368-76.
56. Tang W, Nakamura Y, Zuo H, Yasuoka H, Yang Q, Wang X, et al. Differentiation, proliferation and retinoid receptor status of papillary carcinoma of the thyroid. Pathol Int 2003; 53: 204-13.
57. del Senno L, Rossi R, Gandini D, Piva R, Franceschetti P, degli Uberti EC. Retinoic acid-induced decrease of DNA synthesis and peroxidase mRNA levels in human thyroid cells expressing retinoic acid receptor alpha mRNA. Life Sci 1993; 53:1039-58.
58. Köhrle J, Oertel M, Hoang-Vu C, Schnieders F, Brabant G. Type I 5′-deiodinase a marker for differentiated thyroid carcinoma? Exp Clin Endocrinol 1993; 101: 60-72.
59. Jakobs TC, Schmutzler C, Meissner J, Köhrle J. The promoter of the human type 15′-deiodinase gene: mapping of the transcription start site and identification of a DR+4 thyroid hormone responsive element. Eur J Biochem 1997; 247:288-97.
60. Zhang CY, Kim S, Harney JW, Larsen PR. Further characterisation of thyroid hormone response elements in the human type I iodothyronine deiodinase gene. Endocrinology 1998; 139: 1156-63.
61. Schmutzler C, Schmitt TL, Glaser F, Loos U, Köhrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cel Endocrinol 2002; 189: 145-55.
62. Hoang-Vu C, Schmutzler C, Schwartz I, Bull K, Aust G, Köhrle J, et al. Effects of retinoic acid on protein expression of CD97 and E-cadherin in the human thyroid cell line FTC-133. J Endocrinol Invest 1998; 21 (suppl): 14.
63. Havekes B, Schröder van der Elst JP, Van der Pluijim G, Goslings BM, Morreau J, Romijn JA, et al. Beneficial effects of retinoid acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines. J Endocrinol 2000; 167: 229-38.
64. Hoang-Vu C, Bull K, Schwartz I, Krause G, Schmutler C, Aust G, et al. Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 1104-9.
65. Bassi V, Vitale M, Feliciello A, De Riu S, Rossi G, Fenzi G. Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines. J Clin Endocrinol Metab 1995; 80: 1129-35.
66. Fröhlich E, Brossart P, Wahl R. Effects of retinoids on porcine thyrocytes under different culture conditions. Histochem J 2001; 33: 295-304.
67. Güzey M, Demirpençe E, Criss W, DeLuca HF. Effects of retinoic acid (all-trans and 9-cis) on tumour progression in small-cell lung carcinoma. Biochem Biophys Res Commun 1998; 242: 369-75.
68. Rook AH, Jaworsky C, Nguyen T, Grossman RA, Wolfe JT, Witmaer WK, et al. Beneficial effect of low dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59: 714-9.
69. Coelho SM, Figueiredo MDL, Corbo R, Carvalho DP, Vaisman M. Effect of retinoic acid on metastatic follicular thyroid carcinoma. Endocrinologist 2003; 13: 81-3.
70. 18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107-13.
71. Boerner AR, Petrich T, Wecesser E, Fricke H, Hofmann M, Otto D, et al. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur Nucl Med Mol Imaging 2002; 29: 231-6.
72. Coelho SM, Corbo R, Breitenbach MMD, Carvalho J, Buescu A, Carvalho DP, et al. Retinoic acid receptor (RAR) beta expression as a possible predictive factor of response to redifferentiation therapy in patients with metastatic thyroid carcinoma. Abstract presented during the 75th Annual Meeting, American Thyroid Association. Thyroid 2003; 13: 730.